Balloon angioplasty catheter coating to encourage vessel repair and further reduce restenosis
A method for treating a target vascular portion of a subject including: providing an angioplasty balloon system including a balloon carrying a first therapeutic agent and a second therapeutic agent on a surface of the balloon, wherein the first therapeutic agent is an anti-proliferative or anti-mitotic agent and the second therapeutic agent is a drug that aids in vascular healing on a surface of the balloon; positioning the balloon proximate the target vascular portion; expanding the balloon to engage the target vascular portion; thereby delivering at least a portion of the active agent to the target vascular portion; and withdrawing the balloon from the subject.
1. A method for treating a target vascular portion of a subject with an angioplasty balloon system including an angioplasty balloon, wherein a surface of the angioplasty balloon carries both:
an amphiphilic polymer and paclitaxel directly on a portion of a surface of the angioplasty balloon, and
pro-resolving mediators directly on the portion of the surface of the angioplasty balloon, wherein the pro-resolving mediators are at least partially encapsulated by a polymeric nanoparticle, the method comprising:
positioning the angioplasty balloon proximate the target vascular portion;
expanding the angioplasty balloon to engage the target vascular portion with the portion of the surface of the angioplasty balloon carrying the paclitaxel and the pro-resolving mediators contacting the target vascular portion, thereby simultaneously delivering both the paclitaxel and the pro-resolving mediators to the target vascular portion upon contact of the portion of the surface of the angioplasty balloon with the target vascular portion, wherein the paclitaxel is taken up into a medial layer of vascular tissue at the target vascular portion, while the pro-resolving mediators remain in contact with an intimal surface of the vascular tissue;
subsequently deflating the angioplasty balloon; and
subsequent to the deflating, withdrawing the angioplasty balloon system from the subject.
2. The method of claim 1 , wherein the paclitaxel is a restenosis inhibitor.
3. The method of claim 1 , wherein the pro-resolving mediators are selected from the group consisting of derivatives of omega-3 polyunsaturated fatty acids and omega-6 polyunsaturated fatty acids.
4. The method of claim 1 wherein the angioplasty balloon system further comprises a fluid delivery system coupled to expand the angioplasty balloon by supplying a fluid via a delivery lumen.
5. The method of claim 1 , wherein the polymeric nanoparticle is encapsulated within a platelet membrane.